Navigation Links
Merck's odanacatib increased BMD over 2 years at key fracture sites in Phase IIB study

WHITEHOUSE STATION, N.J., Sept. 16, 2008 Two-year data from a Phase IIB study of odanacatib (formerly MK-0822), an investigational, selective cathepsin-K inhibitor in development for the treatment of osteoporosis by Merck & Co., Inc., demonstrated dose- dependent increases in bone mineral density (BMD) at the total hip, lumbar spine and femoral neck fracture sites and decreased indices of bone resorption compared to placebo in postmenopausal women with low BMD. The results were reported today at the 30th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR).

"Significant BMD increases were seen in the second year of treatment with odanacatib and these 24-month results confirm the positive increases seen at earlier timepoints," said Dr. Michael McClung, study investigator and director of the Oregon Osteoporosis Center in Portland, Oregon. "These data reinforce the potential of odanacatib as a novel treatment option for osteoporosis."

Odanacatib selectively inhibits the cathepsin K enzyme believed to play a central role in osteoclastic bone resorption, particularly in the degradation of the protein component of bone. Inhibition of cathepsin K is a novel approach to the treatment of osteoporosis that differs from those of currently approved treatments.

About the study

The multi-center, double-blind, randomized, placebo-controlled study evaluated doses of 3, 10, 25 or 50 mg of odanacatib administered orally, once-weekly and without regard to the timing of meals or the patient's physical position in 399 postmenopausal women with low BMD (T-scores equal to or less than -2.0 but equal to or greater than -3.5) for 24 months. Participants were provided with 5600 IU weekly, supplemental vitamin D, and 500 mg daily calcium carbonate was given to women with average daily calcium intakes of less than 1000 mg from all sources. The primary study endpoint was the LS mean change in BMD from baseline at the lumbar spine. Secondary endpoints included the LS mean change from baseline in BMD at the total hip, femoral neck, hip trochanter, and distal forearm, and changes in bone turnover based on biochemical markers.

"Bone mineral density" or BMD is the amount of mineralized bone tissue in a certain volume of bone and is one non-invasive measure used to help determine a patient's fracture risk. Odanacatib increased BMD

In the study, once-weekly treatment with 10, 25 and 50 mg of odanacatib significantly increased BMD at the lumbar spine, total hip and femoral neck at 24 months compared to baseline values. The 50 mg dose (n=58) resulted in LS mean percent increases in BMD of

5.48 percent at the lumbar spine compared to baseline values while treatment with placebo (n=61) resulted in a decrease of 0.19 percent compared to baseline (p=0.001). Similarly, the 50 mg dose resulted in LS mean percent increases in BMD of 3.16 percent at the total hip and 3.84 percent at the femoral neck compared to baseline values while treatment with placebo resulted in decreases of 0.93 percent and 0.85 percent respectively compared to baseline (p=0.001). Treatment with 3 mg odanacatib resulted in decreases in BMD at the lumbar spine, total hip and femoral neck. Changes in bone resorption and bone formation

The study also assessed biochemical markers of bone resorption including sCTx (serum C-terminal telopeptides of Type 1 collagen) and uNTx (urinary N-telopeptides/creatinine ratio). Treatment with 50 mg of odanacatib resulted in decreases from baseline of 51.83 percent in uNTx and 30.57 percent in sCTx (p=0.001). sCTx and uNTx changes for placebo were an increase of 32.77 percent and a decrease of 4.62 percent respectively.

Treatment with the 50 mg dose reduced biochemical markers of new bone formation including s-BSAP (bone specific alkaline phosphatase) and sP1NP (serum N-terminal propeptides of type 1 collagen). s-BSAP was reduced from baseline by 13.26 percent (p=0.002) and sP1NP was reduced by 20.20 percent from baseline (p=0.011). s-BSAP and sP1NP changes for placebo were increases of 3.38 percent and 1.29 percent respectively.

Safety results with odanacatib

The number of patients experiencing a drug-related adverse experience was similar between the 50 mg odanacatib group and placebo (34.6 percent and 39.8 percent respectively). Likewise, the discontinuation rates due to drug-related adverse experiences were similar between the 50 mg odanacatib group and placebo (7.7 percent and 4.8 percent respectively). For the 50 mg odanacatib group, the most common drug-related adverse experiences, as assessed by investigators, were nausea, headache, rash and muscle spasms. There was no dose-dependent increase in the incidence of skin adverse experiences or upper respiratory tract infections observed through 24 months.

Phase III study underway

The effect of odanacatib 50 mg on vertebral, hip and non-vertebral fractures is currently being evaluated in a large, global Phase III study.


Contact: Ron Rogers
Merck & Co., Inc.

Related medicine news :

1. Cord Blood America CEO Announces Aggressive Acquisition Strategy, Increased Investor Relations Efforts, New Stem Cell Storage Models
2. Army personnel show increased risk for migraine
3. Physician Recruiting Standard Reveals Larger Populations Experiencing Increased Doctor Shortage
4. Celsius Holdings Reports Increased Revenue 2nd Quarter Revenue Increased 166%
5. Average Annual Medical Premium Costs Increased 6%, Says 2008 Benefit Plan Report from C&B Consulting
6. Social Security Attorneys Prepare for Increased Baby Boomer SSI Claims
7. Sleep apnea linked to increased risk of death
8. Drinking in excess associated with increased risk for metabolic syndrome
9. New study finds smoking predicts increased stroke risk for your spouse
10. Grupo Casa Saba Announces Sales and Operating Income Increased 14.05% and 13.45%, Respectively
11. Responding to Increased Incidence of Obesity and Associated Health Issues, The HealthCentral Network Launches Site to Support those Struggling with Weight
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... ... it has been awarded a fixed price per sprint agile development contract to ... at $34 million over five years, provides software engineering, infrastructure, as well as ...
(Date:12/1/2015)... ... December 01, 2015 , ... TCS Healthcare Technologies (TCS), a ... health arenas, is pleased to announce that VIP Care Services, a Caprock Health ... the ACUITY Complete Care™ Management to back their collaborative catastrophic case management initiatives. ...
(Date:12/1/2015)... ... ... XTC Semifinals 2016 - CES, Las Vegas, Nevada - Extreme ... 2016, the world’s largest Consumer Electronic Show, where they will present to a panel ... Pacific Investments Veronica Serra, and venture capitalist Tim Draper among many other top names ...
(Date:12/1/2015)... Aliso Viejo, CA (PRWEB) , ... December 01, 2015 , ... ... any length of footage, and with full control over customization, the possibilities are truly ... color, frame rate, position randomization, overlay depth position, vertical flip, horizontal flip, depth of ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... Modern Luxury’s Angeleno Magazine as a Modern Man for 2015. , Angeleno ... publisher in the United States. Established in 1994, Modern Luxury includes more than ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Dec. 1, 2015  AccuTEC Blades, a leader ... corporate logo and brand identity program. The new ... engineering of bladed products where "the edge makes ... --> Serving manufacturers and distributors of ... glass equipment, AccuTEC,s product lines include those acquired ...
(Date:12/1/2015)... Dec. 1, 2015  Six months of adjunctive metformin therapy ... 1 diabetes, according to new research from T1D Exchange ... may have a beneficial effect on measures of obesity, including ... of the Journal of the American Medical Association , ... effect of metformin on overweight and obese adolescents with type ...
(Date:12/1/2015)... During the recent 2015 Transcatheter Cardiovascular ... CA , Medinol Ltd. continued to introduce ... a satellite symposium, "The BioNIR eDES: The Role ... a renowned physician panel discussed the key attributes ... Stent System and the Medinol eDES Coronary Stent ...
Breaking Medicine Technology: